This week in health equity and access: Medicaid cuts; mailed FIT outreach; EEOC pregnancy rules; GLP-1 Bridge access; and 2027 policy shifts.
|Articles|April 12, 2012
Blazing a Trail: Pioneer ACOs Test Strategies with Five Pay Options
Advertisement
Physicians at Beth Israel Deaconess Medical Center in Boston are among the first to test Medicare accountable care, but they did not go all-in right away.
The Beth Israel Deaconess Physician Organization chose a slow start from among the options offered by federal health officials who are testing five payment models on 32 accountable care organizations that launched in January.
Read the full story:
Source: ModernHealthcare.com
For Beth Israel doctors, that strategy allows some breathing room to adapt for a year before any financial risks kick in, said Roberta Zysman, the physician organization's executive director.
Advertisement
Related to this article
First-line IVF produced more live births than IUI within 7 months in couples with unexplained infertility.
Elafibranor and seladelpar normalized ALP in most patients with primary biliary cholangitis whose ALP was below the usual escalation threshold.
The FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck cancer.
Most patients with MASH stay on resmetirom at 1 year, but Medicaid coverage was tied to lower odds of filling a first prescription within 30 days.
A 20-year review traces how immune checkpoint inhibitors became a cornerstone of lung cancer treatment.
David T. Plante, MD, PhD, explains that separating mood-related sleepiness from primary hypersomnia relies on the course of illness and sleep testing.
Phase 3 Viti-Up trials show Rinvoq (upadacitinib) JAK inhibitor boosts facial and body repigmentation in nonsegmental vitiligo, with familiar safety.
Advertisement
Advertisement
Trending on AJMC
1
Survodutide Meets CV Safety End Point in SYNCHRONIZE-CVOT
2
FDA Approves First Dual-Targeted Therapy for Advanced HNSCC
3
Pharmacy, Claims Data Show High Resmetirom Persistence in MASH
4
Phase 3 Data Back ALP Normalization as Treatment Goal in PBC
5